Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NKTR-181

Small molecule · developed by Nektar Therapeutics

Phase 3 Most advanced trial (none active)
NKTR Developer
2 Registered trials

What is NKTR-181?

NKTR-181 is an orally administered tablet studied in osteoarthritis of the knee, low back pain, and chronic pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Musculoskeletal
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02367820 Phase 3 Low Back Pain Completed NKTR
NCT01619839 Phase 2 Osteoarthritis of the Knee Completed NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic PainLow Back PainOsteoarthritis of the Knee

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind NKTR-181

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.